APA (7th ed.) Citation

Lange, T., Ernst, T., Gruber, F. X., Maier, J., Cross, M., Müller, M. C., . . . Pfirrmann, M. (2013, May). The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica.

Chicago Style (17th ed.) Citation

Lange, Thoralf, Thomas Ernst, Franz X. Gruber, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus, and Markus Pfirrmann. "The Quantitative Level of T315I Mutated BCR-ABL Predicts for Major Molecular Response to Second-line Nilotinib or Dasatinib Treatment in Patients with Chronic Myeloid Leukemia." Haematologica May. 2013.

MLA (9th ed.) Citation

Lange, Thoralf, et al. "The Quantitative Level of T315I Mutated BCR-ABL Predicts for Major Molecular Response to Second-line Nilotinib or Dasatinib Treatment in Patients with Chronic Myeloid Leukemia." Haematologica, May. 2013.